MCID: ADR016
MIFTS: 54

Adrenal Cortical Carcinoma malady

Categories: Genetic diseases, Rare diseases, Cancer diseases, Cardiovascular diseases, Nephrological diseases, Reproductive diseases, Endocrine diseases

Aliases & Classifications for Adrenal Cortical Carcinoma

About this section
Sources:
49OMIM, 33MalaCards, 10Disease Ontology, 11diseasecard, 45NIH Rare Diseases, 12DISEASES, 51Orphanet, 67UniProtKB/Swiss-Prot, 36MeSH, 65UMLS, 47Novoseek, 24GTR, 42NCIt, 59SNOMED-CT, 66UMLS via Orphanet, 28ICD10 via Orphanet, 37MESH via Orphanet, 34MedGen, 27ICD10, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Adrenal Cortical Carcinoma:

Name: Adrenal Cortical Carcinoma 49 33 10 11
Adrenocortical Carcinoma 33 10 45 12 51 67 36 65
Hereditary Adrenocortical Carcinoma 67 24
Carcinoma Adrenocortical 47 24
Adrenocortical Carcinoma, Hereditary 65
Malignant Neoplasm of Adrenal Cortex 65
Adrenocortical Carcinoma, Pediatric 65
 
Pediatric Adrenocortical Carcinoma 67
Carcinoma of the Adrenal Cortex 10
Aplasia Cutis Congenita 65
Adrenocortical Cancer 47
Adcc 67
Acc 45

Characteristics:

Orphanet epidemiological data:

51
adrenocortical carcinoma:
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe); Age of onset: Childhood

HPO:

61
adrenal cortical carcinoma:
Inheritance: autosomal recessive inheritance


Classifications:



External Ids:

OMIM49 202300
Disease Ontology10 DOID:3948
MeSH36 D018268
NCIt42 C9325
Orphanet51 1501
SNOMED-CT59 2227007, 255035007
UMLS via Orphanet66 C0206686
ICD10 via Orphanet28 C74.0
MESH via Orphanet37 D018268
ICD1027 C74.0
UMLS65 C0206686, C0282160, C0346402 C1859972, C1859973, more

Summaries for Adrenal Cortical Carcinoma

About this section
OMIM:49 Adrenocortical carcinoma (ADCC) is a rare but aggressive childhood tumor, representing about 0.4% of childhood tumors,... (202300) more...

MalaCards based summary: Adrenal Cortical Carcinoma, also known as adrenocortical carcinoma, is related to adrenal cortical adenocarcinoma and obesity, and has symptoms including adrenocortical carcinoma An important gene associated with Adrenal Cortical Carcinoma is TP53 (Tumor Protein P53), and among its related pathways are Prostaglandin Synthesis and Regulation and Corticotropin-releasing hormone. Affiliated tissues include cortex, adrenal cortex and adrenal gland, and related mouse phenotypes are adipose tissue and muscle.

Disease Ontology:10 An adrenal cortex cancer that forms in the outer layer of tissue of the adrenal gland and that has material basis in abnormally proliferating cells derives from epithelial cells.

UniProtKB/Swiss-Prot:67 Adrenocortical carcinoma: A malignant neoplasm of the adrenal cortex and a rare childhood tumor. It occurs with increased frequency in patients with Beckwith-Wiedemann syndrome and Li-Fraumeni syndrome.

Wikipedia:68 Adrenocortical carcinoma, also adrenal cortical carcinoma (ACC) and adrenal cortex cancer, is an... more...

Related Diseases for Adrenal Cortical Carcinoma

About this section

Diseases related to Adrenal Cortical Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 145)
idRelated DiseaseScoreTop Affiliating Genes
1adrenal cortical adenocarcinoma32.2CYP11B2, HSD11B2, PRKAR1A
2obesity29.2CYP19A1, HSD11B2, IGF2, MC2R, PRKAR1A
3adrenocortical carcinoma with pure aldosterone hypersecretion12.4
4adrenal carcinoma11.7
5aplasia cutis congenita, nonsyndromic11.6
6hereditary motor and sensory neuropathy with agenesis of the corpus callosum11.6
7proud syndrome11.4
8acetyl-coa carboxylase deficiency11.3
9aicardi syndrome11.3
10aplasia cutis congenita11.3
11aplasia cutis congenita intestinal lymphangiectasia11.3
12li-fraumeni syndrome11.1
13salivary gland adenoid cystic carcinoma10.6
14isolated corpus callosum agenesis10.5
15prion disease10.4IGF2, TP53
16goiter, multinodular 1, with or without sertoli-leydig cell tumors10.4IGF2, TP53
17oxyphilic adenoma10.3HSD11B2, SYP
18thoracic benign neoplasm10.3HSD11B2, SYP
19brain glioma10.3SYP, TP53
20chronic rhinitis10.3SYP, TP53
21thalassemia10.3
22cerebellar medulloblastoma10.3SYP, TP53
23childhood infratentorial neoplasm10.3SYP, TP53
24fallopian tube serous papilloma10.3SYP, TP53
25lymphoma10.3
26space motion sickness10.3SYP, TP53
27scabies10.3SYP, TP53
28adult choroid plexus cancer10.3SYP, TP53
29lung benign neoplasm10.3SYP, TP53
30spondylocostal dysostosis-anal and genitourinary malformations syndrome10.3CYP11A1, CYP21A2
31pilocytic astrocytoma of cerebellum10.3SYP, TP53
32hypoaldosteronism, congenital, due to cmo ii deficiency10.3CYP11B2, HSD11B2
33fallopian tube teratoma10.3SYP, TP53
34common bile duct disease10.3PRKAR1A, TP53
35ceruminous carcinoma10.3
36acinar cell carcinoma of pancreas10.3
37melanotic neuroectodermal tumor10.3SYP, TP53
38pleomorphic carcinoma10.3SYP, TP53
39sarcoma10.3
40leukemia10.3
41endotheliitis10.3
42caroli disease10.2SYP, TP53
43dysmorphism-short stature-deafness-disorder of sex development syndrome10.2NR0B1, NR5A1
44dcx-related disorders10.2CYP17A1, CYP21A2
45actg2-related disorders10.2NR0B1, NR5A1
46cardiovascular organ benign neoplasm10.2SYP, TP53
47breast cancer10.2
48arthritis10.2
49cone dystrophy10.2
50eosinophilic meningitis10.2

Graphical network of the top 20 diseases related to Adrenal Cortical Carcinoma:



Diseases related to adrenal cortical carcinoma

Symptoms for Adrenal Cortical Carcinoma

About this section

Symptoms by clinical synopsis from OMIM:

202300

Clinical features from OMIM:

202300

HPO human phenotypes related to Adrenal Cortical Carcinoma:

id Description Frequency HPO Source Accession
1 adrenocortical carcinoma HP:0006744

Drugs & Therapeutics for Adrenal Cortical Carcinoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Bexxar15 41 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa June 2003
FDA Label: Bexxar
Disease/s that Drug Treats:Non-Hodgkin's Lymphoma
Indications and Usage:15 BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directedradiotherapeutic antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin'slymphoma who have progressed during or after rituximab therapy,including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1)Determination of the effectiveness of the BEXXAR therapeutic regimen isbased on overall response rates in patients whose disease is refractory tochemotherapy and rituximab. The effects of the BEXXAR therapeuticregimen on survival are not known. (1.1)Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course oftreatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:13 1. B-lymphocyte antigen CD20;2. Low affinity immunoglobulin gamma Fc region receptor III-B;3. Complement C1r subcomponent;4. Complement C1q subcomponent subunit A;5. Complement C1q subcomponent subunit B;6. Complement C1q subcomponent subunit C;7. Low affinity immunoglobulin gamma Fc region receptor III-A;8. High affinity immunoglobulin gamma Fc receptor I;9. Low affinity immunoglobulin gamma Fc region receptor II-a;10.Low affinity immunoglobulin gamma Fc region receptor II-b;11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:15 
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-592 dependent cytotoxicity, and CD20-mediated apoptosis.
2
Perjeta15 41 PERTUZUMAB Genentech June 2012
FDA Label: Perjeta
Disease/s that Drug Treats:HER2+ metastatic breast cancer
Indications and Usage:15 PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment ofpatients with HER2-positive metastatic breast cancer (MBC) who havenot received prior anti-HER2 therapy or chemotherapy for metastaticdisease. (1.1) Use in combination with trastuzumab and docetaxel as neoadjuvanttreatment of patients with HER2-positive, locally advanced,inflammatory, or early stage breast cancer (either greater than 2 cm indiameter or node positive) as part of a complete treatment regimen forearly breast cancer. This indication is based on demonstration of animprovement in pathological complete response rate. No data areavailable demonstrating improvement in event-free survival or overallsurvival. (1.2, 2.1, 14.2)Limitations of Use: The safety of PERJETA as part of a doxorubicin-containing regimenhas not been established. The safety of PERJETA administered for greater than 6 cycles forearly breast cancer has not been established.
DrugBank Targets:13 1. Receptor tyrosine-protein kinase erbB-2
Mechanism of Action:15 
Target: mitogen-activated protein (MAP) kinase, phosphoinositide 3-kinase445 (PI3K)
Action: inhibitor of ligand-initiated intracellular signaling
FDA: Pertuzumab targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2) and, thereby, blocks ligand-dependent heterodimerization of HER2 with other HER family members, including EGFR, HER3, and HER4. As a result, pertuzumab inhibits ligand-initiated intracellular signaling through two major signal pathways, mitogen-activated protein (MAP) kinase, and phosphoinositide 3-kinase (PI3K). Inhibition of these signaling pathways can result in cell growth arrest and apoptosis, respectively. In addition, pertuzumab mediates antibody-dependent cell-mediated cytotoxicity (ADCC). While pertuzumab alone inhibited the proliferation of human tumor cells, the combination of pertuzumab and trastuzumab augmented anti-tumor activity in HER2-overexpressing xenograft models.
3
Unituxin15 41 DINUTUXIMAB United Therapeutics March 2015
FDA Label: Unituxin
Disease/s that Drug Treats:pediatrics with high-risk neuroblastoma
Indications and Usage:15 Unituxin is a GD2-binding monoclonal antibody indicated, incombination with granulocyte-macrophage colony-stimulating factor(GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for thetreatment of pediatric patients with high-risk neuroblastoma whoachieve at least a partial response to prior first-line multiagent,multimodality therapy. (1)
DrugBank Targets:13 1. Ganglioside GD2
Mechanism of Action:15 
Target: GD2
Action: inducer of cell lysis through ADCC and CDC
FDA: Dinutuximab binds to the glycolipid GD2. This glycolipid is expressed on neuroblastoma cellsand on normal cells of neuroectodermal origin, including the central nervous system andperipheral nerves. Dinutuximab binds to cell surface GD2 and induces cell lysis of GD2-expressing cells through antibody-dependent cell-mediated cytotoxicity (ADCC) andcomplement-dependent cytotoxicity (CDC).
4
Portazza15 NECITUMUMAB Eli Lilly November 2015
FDA Label: Portazza
Disease/s that Drug Treats:metastatic squamous non-small cell lung cancer
Indications and Usage:15 PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. (1.1) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. (1.2, 5.6, 14.2)
DrugBank Targets: -
Mechanism of Action:15 
Target: EGFR
Action: blocks the binding of EGFR to its ligands
FDA: Necitumumab is a recombinant human lgG1 monoclonal antibody that binds to the human epidermal growth factor receptor (EGFR) and blocks the binding of EGFR to its ligands. Expression and activation of EGFR has been correlated with malignant progression, induction of angiogenesis, and inhibition of apoptosis. Binding of necitumumab induces EGFR internalization and degradation in vitro. In vitro, binding of necitumumab also led to antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. In in vivo studies using xenograft models of human cancer, including non-small cell lung carcinoma, administration of necitumumab to implanted mice resulted in increased antitumor activity in combination with gemcitabine and cisplatin as compared to mice receiving gemcitabine and cisplatin alone.

Drugs for Adrenal Cortical Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 137)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
CisplatinapprovedPhase 3, Phase 2, Phase 1254015663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
2
MitotaneapprovedPhase 3, Phase 2953-19-04211
Synonyms:
(+-)-1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane
(2,4'-Dichlorodiphenyl)dichloroethane
(o,p)-DDD
1,1-Dichloro-2,2-bis(2,4'-dichlorophenyl)ethane
1,1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane
1,1-Dichloro-2-(p-chlorophenyl)-2-(o-chlorophenyl)ethane
1-(2-Chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane
1-Chloro-2-(2,2-dichloro-1-(4-chlorophenyl)ethyl)benzene
1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene
2,2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane
2,4'-Ddd
2,4'-Dichlorodiphenyldichloroethane
2,4'-Dichlorophenyldichlorethane
2-(2-Chlorophenyl)-2-(4-chlorophenyl)-1,1-dichloroethane
2-(o-Chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloroethane
25925_FLUKA
25925_SIGMA
35485_FLUKA
35485_RIEDEL
49015_SUPELCO
53-19-0
AC1L1HNV
AC1Q3H13
AI3-07575
BRN 2056007
BSPBio_002517
Bristol Myers Squibb Brand of Mitotane
Bristol-Myers Squibb Brand of Mitotane
C 3010
C14H10Cl4
CB 313
CB-313
CB313
CCRIS 4397
CHEMBL1670
CID4211
Chloditan
Chlodithan
Chlodithane
D00420
D008939
DB00648
DivK1c_000703
EINECS 200-166-6
EU-0100251
Ethane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)- (8CI)
HMS1923K19
HMS2091E07
HMS502D05
HSDB 3240
IDI1_000703
KBio1_000703
KBio2_002505
KBio2_005073
KBio2_007641
KBio3_002017
 
KBioGR_001237
KBioSS_002513
Khloditan
Khlodithan
LS-185
Lopac0_000251
Lysodren
Lysodren (TN)
MLS001335899
MLS001335900
MLS002152914
MLS002153233
Mitotan
Mitotane
Mitotane (JAN/USP/INN)
Mitotane [USAN:INN:JAN]
Mitotano
Mitotano [INN-Spanish]
Mitotanum
Mitotanum [INN-Latin]
MolPort-001-779-578
Mytotan
NCGC00015226-03
NCGC00015226-09
NCGC00091374-01
NCGC00091374-02
NCGC00091374-03
NCGC00091374-04
NCGC00091374-05
NCGC00091374-06
NCI-C04933
NCI60_003688
NINDS_000703
NSC 38721
NSC-38721
NSC38721
PS694_SUPELCO
Prestwick_75
SMR000326696
SPBio_000792
SPECTRUM330082
ST51016017
Spectrum2_000916
Spectrum3_000869
Spectrum4_000709
Spectrum5_002060
Spectrum_001959
UNII-78E4J5IB5J
WLN: GYGYR BG&R DG
mitotane
o,p'-DDD
o,p'-Dichlorodiphenyldichloroethane
o,p'-TDE
o,p-DDD
o,p-Tde
ortho,para DDD
ortho,para-DDD
3
Doxorubicinapproved, investigationalPhase 3, Phase 2, Phase 1158223214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
4
StreptozocinapprovedPhase 3918883-66-429327
Synonyms:
-nitrosomethylharnstoff
1-methyl-1-nitroso-3-[(2S,3R,4R,5S,6R)-2,4,5-trihydroxy-6-(hydroxymethyl)oxan-3-yl]urea
18883-66-4
2-Deoxy-2-(((methylnitrosoamino)carbonyl)amino)-D-glucopyranose
2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose
2-Deoxy-2[[(methylnitrosoamino)-carbonyl]amino]-D-glucopyranose
2-deoxy-2-{[methyl(nitroso)carbamoyl]amino}-alpha-D-glucopyranose
AB00513906
AC1L1H7V
Ambap18883-66-4
BCBcMAP01_000142
BPBio1_000754
BSPBio_000684
BSPBio_002734
C07313
CHEBI:9288
CHEMBL1603
CID29327
D-Glucose, 2-deoxy-2-(((methylnitrosoamino)carbonyl)amino)- (9CI)
D05932
DB00428
DivK1c_000531
Estreptozocina
HMS1921A07
HMS2092I09
HMS501K13
IDI1_000531
KBio1_000531
KBio2_001440
KBio2_004008
KBio2_006576
KBio3_001954
KBioGR_001768
KBioSS_001440
MolPort-003-665-493
N-(Methylnitrosocarbamoyl)-alpha-D-glucosamine
N-D-Glucosyl-(2)-N'-nitrosomethylharnstoff
 
N-D-Glucosyl-(2)-N'-nitrosomethylurea
N-D-Glucosyl-(2)-n'
N-D-Glucosyl-(2)-n'-nitrosomethylurea
NCGC00178500-01
NCGC00178500-02
NINDS_000531
Prestwick3_000732
S0130_SIAL
S0130_SIGMA
S1312_Selleck
SMP1_000282
SPBio_000243
SPECTRUM1500543
STREPTOZOTOCIN
STRZ
Spectrum2_000062
Spectrum3_001087
Spectrum4_001244
Spectrum5_001047
Spectrum_000960
Streptozocin
Streptozocin (USAN/INN)
Streptozocin, Zanosar, STZ,Streptozotocin
Streptozocine
Streptozocine [INN-French]
Streptozocinium
Streptozocinium [Latin]
Streptozocinum
Streptozocinum [INN-Latin]
Streptozotocin
UNII-5W494URQ81
ZINC03977737
Zanosar
Zanosar (TN)
alkylating agent
binds to DNA
streptozocin
streptozosin
5
Fentanylapproved, illicit, investigationalPhase 3705437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
6
Mifepristoneapproved, investigationalPhase 314384371-65-355245
Synonyms:
(11beta,17beta)-11-(4-(Dimethylamino)-phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one
(11beta,17beta)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
(11beta,17beta)-11-[4-(dimethylamino)phenyl]-17-hydroxy-17-prop-1-yn-1-ylestra-4,9-dien-3-one
(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide
(8S,11R,13S,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
(E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide
11-(4-DIMETHYLAMINO-PHENYL)-17-HYDROXY-13-METHYL-17-PROP-1-YNYL-1,2,6,7,8,11,12,13,14,15,16,17-DODEC AHYDRO-CYCLOPENTA[A]PHENANTHREN-3-ONE
11-(4-DIMETHYLAMINO-phenyl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,13,14,15,16,17-dodec ahydro-cyclopenta[a]phenanthren-3-one
11beta-(4-(Dimethylamino)phenyl)-17-hydroxy-21-methyl-19-nor-17alpha-pregna-4,9-dien-20-m-3-on
11beta-(4-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-on
11beta-(4-(N,N-Dimethylamino)phenyl)-17alpha-(prop-1-ynyl)-delta4,9-estradiene-17beta-ol-3-one
11beta-(4-Dimethyl-?amino)-?phenyl-17beta-hydroxy-17-(1-propynyl)-?estra-4,9-dien-3-one
11beta-(p-(Dimethylamino)phenyl)-17beta-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one
122742-25-0
17-beta-Hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oestra-4,9-dien-3-one
404951-53-7
83203-42-3
84371-65-3
AC1L1IOO
AC1O62SB
Ambap84371-65-3
BIDD:PXR0123
BPBio1_000262
BRD-K37270826-001-04-5
BRN 5779404
BSPBio_000238
C-1073
C07652
C29H35NO2
CHEBI:50692
CHEMBL157
CHEMBL356066
CI-1073
CID55245
CID6445533
CPD000058481
Contragest Brand of Mifepristone
Corlux
D00585
D015735
DB00834
Dacinostat
Danco Brand of Mifepristone
EC-000.2469
EU-0100801
Exelgyn Brand of Mifepristone
FT-0082666
HMS1568L20
HMS2052L05
HMS2090L22
HSCI1_000369
HSDB 6841
I14-11726
Korlym
LAQ-824
LS-192513
LS-64723
Lopac0_000801
M 8046
 
M8046_SIGMA
MLS000069785
MLS001074115
Mifegyne
Mifeprex
Mifeprex (TN)
Mifepriston
Mifepristona
Mifepristona [Spanish]
Mifepristone (USAN/INN)
Mifepristone Contragest Brand
Mifepristone Danco Brand
Mifepristone Exelgyn Brand
Mifepristone [USAN:INN:BAN]
Mifepristonum
Mifepristonum [Latin]
Mifépristone
MolPort-003-849-222
NCGC00025179-05
NCGC00025179-08
NCGC00179632-01
NVP-LAQ 824
NVP-LAQ824
NVP-LAQ824, Dacinostat, LAQ824
Pictovir
Pictovir (TM)
Prestwick0_000299
Prestwick1_000299
Prestwick2_000299
Prestwick3_000299
Prestwick_570
R 38486
R-38486
R38486
RU 38486
RU 486
RU 486-6
RU-38486
RU-486
RU-486, MIFEPRISTONE
RU-486, RU-38486, Mifegyne, Mifeprex, Mifepristone
RU38486
RU486
S1095_Selleck
S1611_Selleck
SAM001246881
SMR000058481
SPBio_002457
Spectrum5_002045
TL8005515
UNII-320T6RNW1F
UNII-V10P524501
VGX-410
VGX-410C
VX-410
ZINC03831128
ZK 98296
ZK-98296
ZK98296
mifepristone
nchembio.313-comp12
7
HydrocortisoneapprovedPhase 3, Phase 258350-23-75754, 657311
Synonyms:
(11beta)-11,17,21-Trihydroxypregn-4-ene-3,20-dione
1 Hydrocortisone maximum strength
11-Hydrocortisone
11-beta-Hydrocortisone
11-beta-Hydroxycortisone
11a-Hydroxycorticosterone
11alpha-Hydroxycorticosterone
11b,17,21-Trihydroxyprogesterone
11b-Hydrocortisone
11b-Hydroxycortisone
11beta,17,21-Trihydroxyprogesterone
11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione
11beta-Hydrocortisone
11beta-Hydroxycortisone
11beta-hydrocortisone
11β-hydrocortisone
17-Hydroxycorticosterone
17a-Hydroxycorticosterone
17alpha-Hydroxycorticosterone
2v95
4-Pregnen-11beta,17alpha,21-triol-3,20-dione
4-Pregnene-11alpha,21-triol 3,20-dione
4-Pregnene-11b,17a,21-triol-3,20-dione
50-23-7
8056-08-4
80562-38-5
8063-42-1
999 Itch Relieving
A-hydrocort
AC-12902
AC1L1L2B
ACETASOL HC
ACETIC ACID W/ HYDROCORTISONE
AI3-25006
AKOS001582651
Acticort
Acticort (TN)
Advanced Hydrocortisone
Aeroseb HC
Aeroseb-HC
Ala-Cort
Ala-Scalp
Alacort
Algicirtis
Alphaderm
Amberin
Anflam
Anti Itch
Anti Itch maximum strength
Anti Itch maximum strength plus
Anti-inflammatory hormone
Anti-itch
Anti-itch Scalp Relief Maximum Strength
Anucort
Anucort-HC
Anusol HC
Anusol HC (TN)
Apres Peel Soothing Balm
Aquacort
Aquanil HC
Atopalm Maximum Strength Anti-itch
Atopalm Moisturizing Hydrocortisone
Aveeno Hydrocortisone Anti Itch
B48448A1-24BA-47CA-8D9E-43E5BC949386
BPBio1_000544
BRD-K93568044-001-03-1
BSPBio_000494
Balneol-hc
Barseb HC
Basan-Corti
Beta-hc
Bio-0648
Bioelements Immediate Comfort Hydrocortisone
Budpak Anti-itch
C00735
C21H30O5
CCRIS 5854
CHEBI:17650
CHEMBL389621
CID5754
COR-OTICIN
CPD000653523
CaldeCORT Spray
Caldecort
Care One Hydrocortisone maximum strength
Cetacort
Chronocort
Cicatricure Ultra Moisturizing
Clear aid
Cleiton
Cobadex
Colocort
Colocort (TN)
Compound F
Compound F (kendall)
Cor-Tar-Quin
Corhydron
Cort-Dome
Cort-Quin
Cortaid 12-hour Advanced Anti-Itch
Cortaid Intensive Therapy Cooling
Cortaid Maximum Strength
Cortanal
Cortef
Cortef (TN)
Cortenema
Cortesal
Corticreme
Cortifair
Cortifan
Cortifoam
Cortiment
Cortisol
Cortisol alcohol
Cortisol, Hydrocortisone
Cortisolonum
Cortisone
Cortisone Cream Intensive Healing
Cortisone Maximum Strength
Cortisone maximum strength
Cortisporin
Cortisporin Otico
Cortispray
Cortizol
Cortizone 10
Cortizone 10 Cooling Cream Anti-itch
Cortizone 10 Cooling Relief
Cortizone 10 Easy Relief
Cortizone 10 Hydratensive Healing Anti Itch
Cortizone 10 Hydratensive Soothing Anti Itch
Cortizone 10 Intensive Healing
Cortizone 10 Intensive Healing Feminine Itch Relief
Cortizone 10 Intensive Healing For Eczema
Cortizone 10 Plus
Cortizone 10 Poison Ivy Relief Pads
Cortolotion
Cortonema
Cortoxide
Cortril
Cremesone
Cremicort-H
Cutisol
Cvs Anti-itch Hydrocortisone
Cvs Cools Itch Fast
Cvs Cortisone
Cvs Pharmacy Anti-itch
Cyclodextrin-encapsulated hydrocortisone
D00088
DB00741
DB07886
Delacort
Derm-Aid
Dermacort
Dermacort Anti-Itch
Dermaquest Skin Therapy Post-skin Resurfacing Balm
Dermarest Eczema Medicated
Dermaspray
Dermil
Dermocortal
Dermolate
Dg Health Hydrocortisone
Dg Health Hydrocortisone Cream Maximum Strength
Dihydrocostisone
Dioderm
Dome-cort
Domolene-HC
Dr. Sheffield Hydrocortisone Anti Itch
Drotic
Duane Reade
Duane Reade hydrocortisone
Duane Reade hydrocortisone plus 12 moisturizers
DuoCort
EINECS 200-020-1
EU-0100594
Ef corlin
Efcorbin
Efcortelan
Efcortelin
Eldecort
Eldercort
Epicort
Epicortisol
Epiderm H
Equaline Anti Itch
Equaline Anti Itch maximum strength
Equate Hydrocortisone
Esiderm H
Evacort
Family Care Hydrocortisone
Family Wellness
Family Wellness Hydrocortisone
Family Wellness Maximum Strength Hydrocortisone
Ficortril
Fiocortril
Fixmyskin Healing Balm Fragrance-free
Fixmyskin Healing Balm Unflavored
Fixmyskin Healing Balm Vanilla Flavor
Fixmyskin Healing Balm Vanilla Fragrance
Flexicort
Foille Insetti
Formu Care Anti Itch maximum strength
Fulton Street Market Anti Itch
Genacort
Genacort (lotion)
Genuine Hydrocortisone
Glycort
Good Neighbor Pharmacy Anti Itch
Good Neighbor Pharmacy Hydrocortisone
Good Neighbor Pharmacy Hydrocortisone Plus 12 Moisturizers
Good Sense Anti Itch
Gyno-Cortisone
H 4001
H-Cort
H-releve Anti-itch
H0135_SIGMA
H0396_SIGMA
H0888_SIGMA
H3160_SIGMA
H4001_SIGMA
H6909_SIGMA
HC
HC #1
HC #4
HC (HYDROCORTISONE)
HMS1569I16
HMS2090M04
HSDB 3339
HYDROCORTISONE AND ACETIC ACID
HYDROCORTISONE IN ABSORBASE
Healerz For Itches
Health Mart Pharmacy Hydrocortisone Maximum Strength Plus 12 Moisturizers
Healthy Accents Cortisone maximum strength
Heb Cort
Heb-Cort
 
Hem-easy Relief Herbal Anti-itch Maximum Itch Relief
Hi-cor
Hidalone
Hidro-Colisona
Hidrocortisona
Hidrocortisona [INN-Spanish]
Hycort
Hycortol
Hycortole
Hydracort
Hydrasson
Hydro Skin
Hydro-Adreson
Hydro-Colisona
Hydro-RX
Hydro-colisona
Hydrocort
Hydrocortal
Hydrocorticosterone
Hydrocortisone
Hydrocortisone (JP15/USP/INN)
Hydrocortisone 1 plus 10
Hydrocortisone Acetate
Hydrocortisone Anti-itch Plus
Hydrocortisone Base
Hydrocortisone Butyrate
Hydrocortisone D
Hydrocortisone HC
Hydrocortisone Intensive Healing Formula
Hydrocortisone Maximum Strength
Hydrocortisone Maximum Strength Plus 12 Moisturizers
Hydrocortisone Plus
Hydrocortisone Plus 12 Moisturizers
Hydrocortisone Probutate
Hydrocortisone Regular Strength
Hydrocortisone Sodium Phosphate
Hydrocortisone Ultra Strength
Hydrocortisone Valerate
Hydrocortisone [INN:BAN:JAN]
Hydrocortisone alcohol
Hydrocortisone anti itch
Hydrocortisone base
Hydrocortisone free alcohol
Hydrocortisone maximum strength
Hydrocortisone solution
Hydrocortisone-Water Soluble
Hydrocortisonum
Hydrocortisonum [INN-Latin]
Hydrocortistab
Hydrocortisyl
Hydrocortone
Hydroskin
Hydroxycortisone
Hysone
Hytisone
Hytone
Hytone (TN)
Hytone lotion
Idrocortisone
Idrocortisone [DCIT]
Incortin-H
Incortin-hydrogen
Intensive Healing Anti Itch
Kaiser Permanente Hydrocortisone
Kendall'S compound F
Kendall's compound F
Kera Hc Hydrocortisone
Kirkland Signature Hydrocortisone Plus maximum strength
Komed HC
Kyypakkaus
LMST02030001
LS-7439
Lacticare HC
Lacticare-HC
Lactisona
Leader Hydrocortisone
Locoid
Loesch Anti-Itch Therapy
Lopac0_000594
Lubricort
Lucky Supersoft MAXIMUM STRENGTH
MLS000069609
MLS001148103
MLS002207135
MLS002222189
Maintasone
Makesense MAXIMUM STRENGTH
Maximum Strength Cortizone 10 Quick Shot 360 Continuous
Maximum Strength Hydrocortisone
Maximum-h
Medicort
Medpride
Meijer Anti Itch
Meijer Anti Itch Cream Plus
Meijer Hydrocortisone
Meijer Hydrocortisone Plus 12 Moisturizers
Members Mark Hydrocortisone
Meusicort
Mildison
Milliderm
MolPort-001-794-637
Monistat Complete Care Instant Itch Relief
NCGC00022848-06
NCGC00022848-07
NCGC00022848-09
NCGC00022848-12
NCI60_000118
NSC 10483
NSC-10483
NSC10483
Natureplex Hydrocortisone Hydro
Neo-Cort-Dome
Neo-Cortef
Neosporin Eczema Essentials Anti Itch
Neosporin-H Ear
Nogenic HC
Nu-derm Tolereen Anti-pruritic
Nutracort
Nystaform-HC
ORLEX HC
Optef
Otalgine
Otic-Neo-Cort-Dome
Otobiotic
Otocort
Otosone-F
Pandel
Pediaderm Hc
Pediotic Suspension
Penecort
Permicort
Piyanping Antiitch
Polcort H
Premier Value Hydrocortisone
Premier Value Hydrocortisone Plus 12 Moisturizers
Preparation H Hydrocortisone
Preparation H Hydrocortisone Cream
Prepcort
Prestwick0_000447
Prestwick1_000447
Prestwick2_000447
Prestwick3_000447
Prestwick_265
Prevex HC
Proactiv Solution Anti-itch Scalp
Procto-pak
Proctocort
Proctocream HC
Proctofoam
Proctosol-hc
Proctozone HC
Procure
Protocort
Publix Hydro
Publix hydro plus
Quadrydern
Quality Choice Hydrocortisone
Quality Choice Hydrocortisone Maximum Strength
Quality Choice Maximum Strength Anti Itch
Racet
Rectasol-HC
Rectoid
Refuge Hc
Reichstein'S substance M
Reichstein's substance M
Remederm HC
Rexall Anti Itch maximum strength relief
Rexall Hydrocortisone 1
Rexall Hydrocortisone plus moisturizers
Rite Aid anti-itch
S1696_Selleck
SAM002264617
SMP1_000156
SMR000059022
SMR000653523
SPBio_002433
Safeway Hydrocortisone Plus 12 Moisturizers
Sanatison
Scalp-Cort
Scalpicin Anti-Itch Maximum Strength
Scalpicin Capilar
Scalpicin Maximum Strength
Scalpicin Scalp Itch Medication Maximum Strength
Schericur
Scheroson F
Shopko Hydrocortisone
Shopko Hydrocortisone Intensive Healing Formula
Shopko Hydrocortisone Maximum Strength
Shopko Hydrocortisone Plus 12 Moisturizers Maximum Strength
Shopko Maximum Strength
Shoprite Hydrocortisone
Sigmacort
Signef
Smart Sense Anti Itch
Smart Sense Anti Itch maximum strength
Smart Sense Hydrocortisone
Solu-cortef
Soothe Rodan Fields
Stie-cort
Stiefcorcil
Sunmark Hydrocortisone
Sunmark Hydrocortisone Plus 12 Moisturizers
Synacort
Systral Hydrocort
Tarcortin
Tecnu Corticool
Texacort
Texacort lotion 25
Thera Plus
Timocort
Topcare Hydrocortisone
Topcare Hydrocortisone Intensive Healing Formula
Topcare Hydrocortisone Plus 12 Moisturizers
Topicort
Transderma H
Traumaide
Truelipids Anti-itch Barrier
U-cort
UNII-WI4X0X7BPJ
UPCMLD-DP133
UPCMLD-DP133:001
Uniderm
Vioform-Hydrocortisone
VoSol HC
Vytone
Walgreens Hydrocortisone Plus 12 Moisturizers
Westcort
Western Family HydroCortisone
Western Family HydroCortisone Plus 12 Moisturizers
Zenoxone
[3H]cortisol
component of Lubricort
component of Neo-Cort-Dome
component of Otalgine
hydrocortisone
8
EpinephrineapprovedPhase 3, Phase 2, Phase 183451-43-45816
Synonyms:
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol
(-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol
(-)-Adrenalin
(-)-Adrenaline
(-)-Epinephrine
(-)-R-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-(−)-adrenaline
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-4-[1-hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
(R)-Adrenaline
(R)-Epinephrine
(−)-adrenaline
02252_FLUKA
1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
1-Adrenalin
1-Epinephrine
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-Benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol
51-43-4
51-43-4 (FREE BASE)
51028-73-0
A0173
AC-13188
AC1L1L7B
ADR ADRENALINE
ADROP
AI3-19015
Adnephrine
Adrenaclick
Adrenal
Adrenalin
Adrenalin (TN)
Adrenalin in Oil
Adrenalin-Medihaler
Adrenalina
Adrenalina [DCIT]
Adrenaline
Adrenaline (JP15)
Adrenaline/Epinephrine
Adrenalinum
Adrenamine
Adrenan
Adrenapax
Adrenasol
Adrenatrate
Adrenine
Adrenodis
Adrenohorma
Adrenosan
Adrenutol
Adrin
Adrine
Ana-Guard
Ana-Kit
Antiasthmatique
Asmatane Mist
Asthma meter mist
Asthma-nefrin
Asthmahaler Mist
Asthmanefrin
Astmahalin
Astminhal
Auvi-q
BIDD:GT0119
Balmadren
Bernarenin
Biorenine
Bosmin
Brevirenin
Bronkaid
Bronkaid Mist
Bronkaid Suspension Mist
Bupivacaine Hcl and Epinephrine
C00788
CCRIS 4812
CHEBI:28918
CHEMBL679
CID5816
Chelafrin
Citanest Forte
Corisol
D-Epifrin
D-Epinephrine
D00095
DB00668
Drenamist
Dylephrin
Dyspne-Inhal
E4250_SIGMA
EINECS 200-098-7
EPI E Z PEN JR
EPIPEN E Z PEN
EPIPEN JR
Epi EZ Pen Jr
Epifrin
Epiglaufrin
Epinefrin
Epinefrin [Czech]
Epinefrina
Epinefrina [INN-Spanish]
Epinephran
Epinephrin
Epinephrine
Epinephrine (USP)
Epinephrine (USP/INN)
Epinephrine [USAN:INN:JAN]
Epinephrine bitartrate
Epinephrine chloride
Epinephrine hydrochloride
Epinephrinum
Epinephrinum [INN-Latin]
Epipen
Epipen (TN)
Epipen Auto-Injector
Epipen EZ Pen
Epipen Jr
Epipen Jr.
Epipen Jr. Auto-Injector
Epipen jr
Epirenamine
Epirenan
Epirenin
Epitrate
Eppy
 
Esphygmogenina
Exadrin
Glaucon
Glaucosan
Glauposine
Glycirenan
HSCI1_000215
HSDB 4289
Haemostasin
Haemostatin
Hektalin
Hemisine
Hemostasin
Hemostatin
Hypernephrin
Hyporenin
IOP
Intranefrin
Iontocaine
Isoptoepinal
Kidoline
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-Adrenaline Base
L-Epinehphrine
L-Epinephrine
L-Epirenamine
L-Methylaminoethanolcatechol
L-epinephrine
LS-156
Levo-Methylaminoethanolcatechol
Levoadrenaline
Levoepinephrine
Levorenen
Levorenin
Levorenine
Levoreninum
Lopac-E-4642
Lyodrin
Lyophrin
Medihaler-Epi
Metanephrin
Methylaminoethanolcatechol
Methylarterenol
Micronefrin
Micronephrine
MolPort-002-051-368
Mucidrina
Myosthenine
Mytrate
NCGC00015417-01
NCGC00142615-01
NCGC00142615-03
NCGC00142615-04
NCGC00142615-05
NCGC00142615-06
NCGC00142615-07
NSC 62786
NSC62786
Nephridine
Nieraline
PDSP1_001120
PDSP2_001104
Paranephrin
Primatene
Primatene Mist
Primatene Mist Refill
Prime Asthma Relief
R-(-)-Epinephrine
R-Adrenaline
RCRA waste no. P042
Racemic Epinephrine
Racepinephrine
Rcra waste number P042
Renagladin
Renaglandin
Renaglandulin
Renaleptine
Renalina
Renoform
Renostypricin
Renostypticin
Renostyptin
SMP1_000227
ST069368
SUS-PHRINE SULFITE-FREE
Scurenaline
Septocaine
Simplene
Sindrenina
Soladren
Sphygmogenin
Stryptirenal
Styptirenal
Supracapsulin
Supradin
Supranefran
Supranephrane
Supranephrine
Supranol
Suprarenaline
Suprarenin
Suprel
Surenine
Surrenine
Sus-Phrine
Sus-phrine
Susphrine
Sympathin I
Takamina
Takamine
Tokamina
Tonogen
Twinject
Twinject 0.15
Twinject 0.3
Twinject 0.30
UNII-YKH834O4BH
Vaponefrin
Vasoconstrictine
Vasoconstrictor
Vasodrine
Vasoton
Vasotonin
adrenaline
bmse000316
d-Adrenaline
epinephrine
l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
l-Adrenalin
l-Adrenaline
l-Epinephine
l-Epinephrine (synthetic)
l-Epirenamine
l-Methylaminoethanolcatechol
levoepinephrine
nchembio747-comp9
9
EtoposideapprovedPhase 3, Phase 2116933419-42-036462
Synonyms:
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
Ambap33419-42-0
BPBio1_000673
BRD-K37798499-001-02-5
BSPBio_000611
Bio1_000489
Bio1_000978
Bio1_001467
C01576
CCRIS 2392
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
EPE
EPEG
ETOP
Epipodophyllotoxin
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
 
Etopol
Etopophos
Etopophos (phosphate salt)
Etoposid
Etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide Phosphate
Etoposide [USAN:INN:BAN:JAN]
Etoposido
Etoposido [INN-Spanish]
Etoposidum
Etoposidum [INN-Latin]
Etosid
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
LS-1214
Lastet
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
NK 171
NSC 141540
NSC-141540
NSC141540
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Prestwick_211
S1225_Selleck
SAM001246880
SMR000112002
SPBio_002532
ST056353
Toposar
UNII-6PLQ3CP4P3
VP 16
VP 16 (pharmaceutical)
VP 16-213
VP 16213
VP-16
VP-16-213
VePESID (TN)
VePesid
Vepesid
Vepesid J
Vepeside
ZINC03830818
ZINC03938684
Zuyeyidal
etoposide
nchembio.573-comp8
nchembio873-comp2
trans-Etoposide
10
IsotretinoinapprovedPhase 31154759-48-25538, 5282379
Synonyms:
(13-cis)-Retinoate
(13-cis)-Retinoic acid
(13cis)-retinoic acid
(2Z,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic acid
(2Z,4E6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid
(7E,9E,11E,13Z)-retinoic acid
(7e,9e,11e,13Z)-Retinoic acid
13 Cis-Retinoic Acid
13 cis retinoic acid
13-RA
13-cis RA
13-cis retinoic acid
13-cis-Retinoate
13-cis-Retinoic acid
13-cis-Vitamin A acid
13-cis-Vitamin a acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)2-cis-4-trans-6-trans-8-trans-nonatetraenoic acid
4-09-00-02388 (Beilstein Handbook Reference)
4759-48-2
97950-17-9
AC-15388
AC1NQZZ4
Absorica
Accutane
Accutane (TN)
Ambap302-79-4
Amnesteem
BML2-E07
BPBio1_000080
BRD-K76723084-001-05-9
BRN 1885770
BSPBio_000072
BSPBio_001331
BSPBio_003345
CCRIS 4286
CHEBI:6067
CHEMBL547
CID5282379
CIP-Isotretinoin
CPD000471891
Claravis
Clarus
D00348
D015474
EINECS 225-296-0
EU-0101081
Epuris
HMS1361C13
HMS1568D14
HMS1791C13
HMS1921D08
HMS1989C13
HMS2092N07
HSDB 3929
IDI1_033801
Isotane
Isotretinoin
Isotretinoin (USP)
 
Isotretinoin Retinoic acid
Isotretinoin Zinc Salt, 13 cis Isomer
Isotretinoin Zinc Salt, 13-cis-Isomer
Isotretinoin [USAN:BAN:INN]
Isotretinoin [USAN:INN:BAN]
Isotretinoina
Isotretinoine
Isotretinoine [INN-French]
Isotretinoino
Isotretinoino [INN-Spanish]
Isotretinoinum
Isotretinoinum [INN-Latin]
Isotrex
LMPR01090021
LS-143465
Lopac0_001081
MLS001074662
MolPort-003-666-394
Myorisan
NCGC00094358-01
NCGC00094358-02
NCGC00094358-03
NCGC00094358-04
NCGC00094358-05
NCGC00094358-06
NCGC00094358-07
NCGC00094358-08
NCGC00094358-09
NCGC00094358-13
Neovitamin A acid
Neovitamin a acid
Prestwick2_000256
Prestwick3_000256
Prestwick_642
R 3255
R3255_SIGMA
Retinoate
Retinoic acid
Ro 4 3780
Ro 4-3780
Ro 43780
Ro-4-3780
Ro-43780
Roaccutan
Roaccutane
Roacutan
SAM002548955
SMR000471891
SPECTRUM1502013
Sotret
Sotret (TN)
Spectrum5_001795
Spectrum5_001937
Teriosal
UNII-EH28UP18IF
Zenatane
cis-RA
cis-Retinoate
cis-Retinoic acid
isotretinoino
11
EtomidateapprovedPhase 2, Phase 35733125-97-236339, 667484
Synonyms:
(+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
(+)-Etomidate
(+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
(+)-etomidate
(R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
(R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
(d)-Etomidate
1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester
1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester
15301-65-2
1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester
3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
3-(1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
33125-97-2
AC-5898
AC1L1VLF
AC1Q34BV
AC1Q64LP
AKOS000548952
Absele
Amidate
Amidate (TN)
Amidate (pharmaceutical)
Amidate, Etomidate
BAS 01947657
BRN 0665833
C07522
C14H16N2O2
CHEBI:129025
CHEMBL23731
CID36339
CPD000010931
D-Etomidate
D005045
D00548
 
DB00292
EINECS 251-385-9
Ethnor
Ethomidate
Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Etomidate
Etomidate (USAN/INN)
Etomidate [USAN:BAN:INN]
Etomidato
Etomidato [INN-Spanish]
Etomidatum
Etomidatum [INN-Latin]
Etomidic acid
HMS1571A04
HMS1612G10
HMS2093P17
Hypnomidate
LS-78232
MLS000034952
MLS001240191
MolPort-000-917-569
Prestwick0_001041
Prestwick1_001041
Prestwick2_001041
R 16659
R 26490
R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
R-26490
R26490
Radenarcon
Radenarkon
S1329_Selleck
SAM002548930
SBB066197
SMR000010931
SPBio_002901
UNII-Z22628B598
ethyl 3-(1-phenylethyl)imidazole-4-carboxylate
12
Tretinoinapproved, investigational, nutraceuticalPhase 3210302-79-45538, 444795
Synonyms:
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
(all-e)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
.beta.-Retinoic acid
13497-05-7 (hydrochloride salt)
15-Apo-beta-caroten-15-oic acid
187175-63-9
1n4h
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoate
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenoic acid (ecl)
302-79-4
5300-03-8
56573-65-0
7005-78-9
9(Z)-Retinoic acid
9-cis-RA
A-Acido (Argentina)
A-Vitaminsyre
A-Vitaminsyre [Denmark]
AC-6824
AC1L9GWO
AC1Q1J2J
AGN 100335
AGN 192013
AKOS000280845
ALRT 1057
AT-RA
ATRA
Aberel
Aberela
Aberela [Norway]
Accutane Roche
Acid A Vit (Belgium, Netherlands)
Acid, Retinoic
Acid, Vitamin A
Acid, all-trans-Retinoic
Acid, beta-all-trans-Retinoic
Acid, trans-Retinoic
Acide retinoique (French)
Acide retinoique (French) (DSL)
Acide retinoique (french) (dsl)
Acnavit
Acnavit [Denmark]
Airol
Aknefug
Aknoten
Alitretinoin
All Trans Retinoic Acid
All Trans-Retinoic Acid
All-(E)-Retinoate
All-(E)-Retinoic acid
All-trans Retinoic Acid
All-trans-Retinoate
All-trans-Retinoic acid
All-trans-Tretinoin
All-trans-Vitamin A acid
All-trans-Vitamin A1 acid
Alltrans-retinoic acid
Amnesteem
Atra-IV
Atragen
Atralin
Avita
Avita (TN)
Avita Gel
Avitoin
Avitoin [Norway]
BAL4079
BIDD:GT0483
BIDD:PXR0081
BML2-E05
BPBio1_000082
BRN 2057223
BSPBio_000074
BSPBio_001500
Betarretin
C00777
CCRIS 3294
CCRIS 7098
CHEBI:15367
CHEMBL38
CID444795
CPD000058245
Claravis
Cordes VAS [Germany]
Cordes vas
D00094
D014212
DB00523
DB00755
DB00982
Dermairol
EINECS 206-129-0
EU-0101061
Effederm
Effederm [France]
Epi-aberel
Eudyna
HMS1361K22
HMS1568D16
HMS1791K22
HMS1921D14
HMS1989K22
HMS2089D20
HMS2092N11
HMS502N05
HSDB 2169
HSDB 7186
I04-0008
I14-2351
IDI1_000903
IDI1_033970
Isotretinoin Retinoic acid
L000833
LGD 100057
LMPR01090019
LS-1154
Lopac0_001061
Lsotretinoin
MLS000028588
MLS001076515
MLS002207234
MLS002222211
MolPort-000-883-857
NCGC00017280-06
NCGC00017280-17
NCGC00021808-04
 
NCGC00021808-05
NCGC00021808-06
NCGC00021808-07
NCGC00021808-09
NCGC00021808-14
NCGC00021808-15
NSC 122758
NSC-122758
NSC122758
Nexret
Obagi
PDT-002-002
Panretin Gel
Panretyn
Potassium Salt, Tretinoin
Prestwick2_000257
Prestwick3_000257
Prestwick_424
R 2625
R0064
R2625_SIGMA
REA
RETINOIC ACID, ALL TRANS
RETINOIC acid
Refissa
Renova
Renova (TN)
Retacnyl
Retin A
Retin A (TN)
Retin-A
Retin-A Micro
Retin-a
Retin-a Micro
Retinoate
Retinoic acid
Retinoic acid, all-trans- (8CI)
Retinova
Retionic Acid
Retionic acid
Retisol-A
Retisol-a
Ro 1-5488
S1653_Selleck
SAM002264647
SMR000058245
SPECTRUM1502016
SR-01000000239
SR-01000000239-14
ST057075
Salt, Tretinoin Potassium
Salt, Tretinoin Sodium
Salt, Tretinoin Zinc
Sodium Salt, Tretinoin
Solage
Sotret
Spectrum5_001746
Spectrum5_001933
Stieva-A
Stieva-a
Stieva-a Forte
TRETINON
Tretin M
Tretin m
Tretin-x
Tretin.x
Tretinoin
Tretinoin (JAN/USP/INN)
Tretinoin (TN)
Tretinoin 0.1% cream or placebo
Tretinoin Cream
Tretinoin Gel Microsphere
Tretinoin Potassium Salt
Tretinoin Sodium Salt
Tretinoin Zinc Salt
Tretinoin [USAN:INN:BAN]
Tretinoin/All-Trans Retinoic Acid
Tretinoina
Tretinoina [INN-Spanish]
Tretinoine
Tretinoine (French)
Tretinoine (french) (einecs)
Tretinoine [INN-French]
Tretinoino
Tretinoino [INN-Spanish]
Tretinoinum
Tretinoinum [INN-Latin]
Tretinx
Tri-Luma
Trétinoïne
UNII-1UA8E65KDZ
UNII-5688UTC01R
UPCMLD-DP097
Vesanoid
Vesanoid (TN)
Vesanoid, Airol, Renova, Atralin, Retin-A, Avita, Tretinoin
Vesnaroid
Vitamin A acid
Vitinoin
WLN: L6UTJ A1 B1U1Y1 & U2U1Y1 & U1VQ C1 C1
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U1VQ C1 C1
Zinc Salt, Tretinoin
[3H]Retinoic acid
all trans-Retinoic acid
all-(E)-Retinoic acid
all-(e)-Retinoic acid
all-trans-Retinoic acid
all-trans-Tretinoin
all-trans-Vitamin A acid
all-trans-Vitamin A1 acid
all-trans-Vitamin a acid
all-trans-Vitamin a1 acid
all-trans-b-Retinoic acid
all-trans-beta-Retinoic acid
b-Retinoic acid
beta all trans Retinoic Acid
beta-Ra
beta-Retinoate
beta-Retinoic Acid
beta-Retinoic acid
beta-all-trans-Retinoic acid
bmse000562
nchembio.154-comp2
trans Retinoic Acid
trans-Retinoate
trans-Retinoic acid
tretinoin
tretinoin liposome
tretinoine (French) (EINECS)
13
DoxilApproved June 1999Phase 3, Phase 2, Phase 1158231703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
14HormonesPhase 3, Phase 211748
15Hormone AntagonistsPhase 3, Phase 210002
16Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 3, Phase 29988
17Anti-Bacterial AgentsPhase 3, Phase 2, Phase 19140
18Contraceptives, PostcoitalPhase 3146
19MitogensPhase 3, Phase 21386
20Epinephryl boratePhase 3, Phase 2, Phase 1834
21Hydrocortisone acetatePhase 3, Phase 2583
22RacepinephrinePhase 3, Phase 2, Phase 1834
23Etoposide phosphatePhase 3, Phase 21169
24Insulin, Globin ZincPhase 3, Phase 24278
25Melanocyte-Stimulating HormonesPhase 398
26Contraceptives, OralPhase 33734
27Hydrocortisone-17-butyratePhase 3, Phase 2583
28Hydrocortisone 17-butyrate 21-propionatePhase 3, Phase 2583
29Cortisol succinatePhase 3, Phase 2583
30AnestheticsPhase 3, Phase 27385
31Contraceptive AgentsPhase 3, Phase 21706
32Anesthetics, IntravenousPhase 3, Phase 21943
33Analgesics, OpioidPhase 32304
34AnalgesicsPhase 39358
35Antineoplastic Agents, HormonalPhase 3, Phase 24256
36Topoisomerase InhibitorsPhase 3, Phase 2, Phase 14081
37Central Nervous System DepressantsPhase 3, Phase 210016
38Anesthetics, GeneralPhase 3, Phase 22274
39Peripheral Nervous System AgentsPhase 3, Phase 218510
40insulinPhase 3, Phase 24278
41beta-endorphinPhase 399
42pancreatic polypeptidePhase 3, Phase 120
43Adrenocorticotropic HormonePhase 3, Phase 2133
44Liver ExtractsPhase 3, Phase 2, Phase 1, Phase 03572
45Antibiotics, AntitubercularPhase 3, Phase 2, Phase 15971
46NarcoticsPhase 32709
47lenograstimPhase 31134
48Fluorodeoxyglucose F18Phase 2, Phase 3356
49Hypnotics and SedativesPhase 2, Phase 32032
50MydriaticsPhase 2, Phase 3525

Interventional clinical trials:

(show top 50)    (show all 58)
idNameStatusNCT IDPhase
1A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical CarcinomaCompletedNCT00924989Phase 3
2Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT)CompletedNCT00094497Phase 3
3Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
4An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00936741Phase 3
5A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeCompletedNCT00569582Phase 3
6Efficacy of Adjuvant Mitotane Treatment (ADIUVO)RecruitingNCT00777244Phase 3
7European Low and Intermediate Risk Neuroblastoma ProtocolRecruitingNCT01728155Phase 3
8Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical TumorActive, not recruitingNCT00304070Phase 3
9Combined FDG-PET and 123I-Iodometomidate Imaging for Adrenal NeoplasiaNot yet recruitingNCT02010957Phase 2, Phase 3
10Trial With Taxotere and Cisplatin in Non-operable Adrenocortical CarcinomaCompletedNCT00324012Phase 2
11Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)CompletedNCT00215202Phase 2
12Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By SurgeryCompletedNCT00848016Phase 2
13A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsCompletedNCT01262235Phase 1, Phase 2
14Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical CancerCompletedNCT01255137Phase 2
15A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical ResectionCompletedNCT00001339Phase 2
16Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical CancerCompletedNCT00071058Phase 2
17Evaluation of 123I-Iodometomidate for Adrenal ScintigraphyCompletedNCT00454103Phase 1, Phase 2
18Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2
19Combination Chemotherapy and Tamoxifen in Treating Patients With Solid TumorsCompletedNCT00002608Phase 2
20Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
21A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single AgentCompletedNCT00264433Phase 2
22RAD001 in Pheochromocytoma or Nonfunctioning CarcinoidCompletedNCT01152827Phase 2
23Surgery and Heated Chemotherapy for Adrenocortical CarcinomaRecruitingNCT01833832Phase 2
24Nivolumab in Treating Patients With Metastatic Adrenocortical CancerRecruitingNCT02720484Phase 2
25Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical CarcinomaRecruitingNCT02673333Phase 2
26Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer PatientsRecruitingNCT00786110Phase 2
27Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland CancerRecruitingNCT00003453Phase 2
28Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeRecruitingNCT02468193Phase 2
29External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain MetastasesRecruitingNCT00637637Phase 2
30Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical CarcinomaActive, not recruitingNCT01514526Phase 2
31Sunitinib in Refractory Adrenocortical CarcinomaActive, not recruitingNCT00453895Phase 2
32Study for the Evaluation of Efficacy of Pembrolizumab (MK-3475) in Patients With Rare TumorsNot yet recruitingNCT02721732Phase 2
33S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by SurgeryTerminatedNCT00002921Phase 2
34IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by SurgeryTerminatedNCT00778817Phase 2
35Treatment Study Using Bevacizumab for Patients With Adrenocortical CarcinomaWithdrawnNCT00469469Phase 2
36Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid TumorsCompletedNCT00003038Phase 1
37Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine FeaturesCompletedNCT01048892Phase 1
38Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
39Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal CancerCompletedNCT00436657Phase 1
40Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
41MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
42Spectroscopy With Surface Coils and DecouplingCompletedNCT00581815Phase 1
43Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical CarcinomaRecruitingNCT01898715Phase 1
44Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)RecruitingNCT01772004Phase 1
45A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni SyndromeActive, not recruitingNCT01981525Phase 1
46Possible New Therapy for Advanced CancerTerminatedNCT01832974Phase 1
47Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerCompletedNCT00436410Phase 0
48Studying Genes in Samples From Younger Patients With Adrenocortical TumorCompletedNCT01528956
49German Adrenocortical Carcinoma RegistryRecruitingNCT00453674
50Evaluation of Side Effects of MitotaneRecruitingNCT00568139

Search NIH Clinical Center for Adrenal Cortical Carcinoma


Cochrane evidence based reviews: adrenocortical carcinoma

Genetic Tests for Adrenal Cortical Carcinoma

About this section

Anatomical Context for Adrenal Cortical Carcinoma

About this section

MalaCards organs/tissues related to Adrenal Cortical Carcinoma:

33
Cortex, Adrenal cortex, Adrenal gland, Lung, Breast, Brain, B cells

Animal Models for Adrenal Cortical Carcinoma or affiliated genes

About this section

MGI Mouse Phenotypes related to Adrenal Cortical Carcinoma:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053758.6CYP11B2, CYP19A1, MC2R, PRKAR1A, TP53
2MP:00053698.4CYP11A1, CYP19A1, HSD11B2, IGF2, PRKAR1A, TP53
3MP:00028738.0CYP11A1, CYP19A1, HSD11B2, NR5A1, PRKAR1A, SYP
4MP:00053857.6CYP11B2, CYP19A1, HSD11B2, IGF2, MC2R, NR5A1
5MP:00053867.5CYP11A1, CYP17A1, CYP19A1, HSD11B2, IGF2, MC2R
6MP:00053787.2CYP11A1, CYP11B2, CYP19A1, IGF2, MC2R, NR5A1
7MP:00053796.8CYP11A1, CYP11B2, CYP19A1, IGF2, MC2R, NR0B1
8MP:00053896.7CYP11A1, CYP11B2, CYP17A1, CYP19A1, IGF2, NR0B1
9MP:00053766.1CYP11A1, CYP11B2, CYP17A1, CYP19A1, HSD11B2, IGF2

Publications for Adrenal Cortical Carcinoma

About this section

Articles related to Adrenal Cortical Carcinoma:

(show all 37)
idTitleAuthorsYear
1
Reduction of Diabetic Macular Edema in the Untreated Fellow Eye Following Intravitreal Injection of Aflibercept. (27183553)
2016
2
Structural correlates of COMT Val158Met polymorphism in childhood ADHD: a voxel-based morphometry study. (25495556)
2015
3
Association of Titanium Mesh and Bovine Pericardium Membrane in the Treatment of Severe Enophthalmos. (26468837)
2015
4
Conventional and advanced MR imaging in infantile Refsum disease. (26701952)
2015
5
Serological markers of viral, syphilitic and toxoplasmic infection in children and teenagers with nephrotic syndrome: case series from mato grosso state, Brazil. (25351544)
2014
6
A novel GATA4 loss-of-function mutation responsible for familial dilated cardiomyopathy. (24366163)
2014
7
Impact of moderate and severe hypodontia and amelogenesis imperfecta on quality of life and self-esteem of adult patients. (23778130)
2013
8
The differential regulation of p38I+ by the neuronal kinase interaction motif protein tyrosine phosphatases, a detailed molecular study. (23932588)
2013
9
Translation initiation is driven by different mechanisms on the HIV-1 and HIV-2 genomic RNAs. (23079111)
2013
10
Reply: Comparison of immediate implant-based versus staged tissue expander breast reconstruction technique. (23446598)
2013
11
The state of surgical ablation for atrial fibrillation in patients with mitral valve disease. (23295553)
2013
12
Pseudohypoparathyroidism type 1a in pregnancy. (24219739)
2013
13
A combined approach for I^-thalassemia based on gene therapy-mediated adult hemoglobin (HbA) production and fetal hemoglobin (HbF) induction. (22460946)
2012
14
Osteoplastic atticoantrotomy with autologous bone chips and a bony attic strut in cholesteatoma surgery. (19953260)
2010
15
Acupuncture for a patient with whiplash-type injury. (20923939)
2010
16
Myocilin mutations are not a major cause of primary congenital glaucoma in Iranian patients. (22737338)
2010
17
The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) mice. (19118829)
2009
18
Patients with IgA nephropathy exhibit high systemic PDGF-DD levels. (19357108)
2009
19
Epithelial and stromal genetic instability linked to tumor suppressor genes in ulcerative colitis-associated tumorigenesis. (18415748)
2008
20
Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics. (18241344)
2008
21
Effects of antiviral agents and HBV genotypes on intrahepatic covalently closed circular DNA in HBeAg-positive chronic hepatitis B patients. (18300356)
2008
22
Improved real-time detection of the H63D and S65C mutations associated with hereditary hemochromatosis using a SimpleProbe assay format. (18624620)
2008
23
Dynamic changes in the cytoskeleton during human spermiogenesis. (16210017)
2005
24
Linkage and association of the mitochondrial aspartate/glutamate carrier SLC25A12 gene with autism. (15056512)
2004
25
Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. (14631387)
2004
26
Opposite effects of Ha-Ras and Ki-Ras on radiation-induced apoptosis via differential activation of PI3K/Akt and Rac/p38 mitogen-activated protein kinase signaling pathways. (14712206)
2004
27
Thyroid-specific transcription factors control Hex promoter activity. (12655000)
2003
28
Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes. (12620642)
2003
29
Peripheral medulloepithelioma: an immunohistochemical, ultrastructural, and cytogenetic study of a rare, chemotherapy-sensitive, pediatric tumor. (12826895)
2003
30
Treatment of recurrent idiopathic priapism with oral baclofen. (12441973)
2002
31
T-type Ca2+ channels and pharmacological blockade: potential pathophysiological relevance. (9512867)
1997
32
Immunohistochemical evaluation of alpha-catenin expression in human breast cancer: preliminary report]. (8177204)
1994
33
Toxic optic neuropathy associated with ethambutol: implications for current therapy. (8071504)
1994
34
Dipeptidyl peptidase II- and IV-like activities in gingival tissue and crevicular fluid from human periodontitis lesions. (1350193)
1992
35
Effect of intravenous insulin treatment on in vivo whole body leucine kinetics and oxygen consumption in insulin-deprived type I diabetic patients. (3553851)
1987
36
Capgras syndrome in a 14-year-old. (7093624)
1982
37
Pediatrics-epitomes of progress: the fetal hydantoin syndrome. (18748159)
1978

Variations for Adrenal Cortical Carcinoma

About this section

Cosmic variations for Adrenal Cortical Carcinoma:

7 (show top 50)    (show all 238)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
1COSM44175TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
2COSM44175TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
3COSM44175TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning3
4COSM44091TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
5COSM44091TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
6COSM44175TP53adrenal gland,NS,adrenal cortical carcinoma,functioning3
7COSM44175TP53adrenal gland,NS,adrenal cortical carcinoma,functioning3
8COSM44816TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
9COSM44288TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
10COSM44288TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
11COSM44288TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
12COSM44091TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
13COSM44081TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
14COSM43931TP53adrenal gland,NS,adrenal cortical carcinoma,functioning3
15COSM43931TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
16COSM43931TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
17COSM43931TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning3
18COSM43931TP53adrenal gland,NS,adrenal cortical carcinoma,functioning3
19COSM43963TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
20COSM44081TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
21COSM44081TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
22COSM43963TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
23COSM43963TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
24COSM44816TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
25COSM44816TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
26COSM10801TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,functioning3
27COSM10801TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
28COSM10790TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
29COSM10790TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
30COSM10790TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
31COSM10801TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
32COSM10801TP53adrenal gland,NS,adrenal cortical carcinoma,functioning3
33COSM44083TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
34COSM44083TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
35COSM44083TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
36COSM10801TP53adrenal gland,NS,adrenal cortical carcinoma,functioning3
37COSM10725TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
38COSM10725TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
39COSM10645TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
40COSM107991TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
41COSM107991TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
42COSM107991TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
43COSM10645TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
44COSM10645TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
45COSM10725TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
46COSM44623TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
47COSM44623TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
48COSM44623TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
49COSM43755TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3
50COSM43755TP53adrenal gland,adrenal gland,adrenal cortical carcinoma,NS3

Expression for genes affiliated with Adrenal Cortical Carcinoma

About this section
Search GEO for disease gene expression data for Adrenal Cortical Carcinoma.

Pathways for genes affiliated with Adrenal Cortical Carcinoma

About this section

Pathways related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.9CYP11A1, HSD11B2
29.3CYP11A1, CYP21A2, STAR
38.6CYP11A1, CYP17A1, CYP19A1, STAR
4
Show member pathways
8.6CYP11A1, CYP11B2, CYP21A2, MC2R, STAR
5
Show member pathways
8.1CYP11A1, CYP11B2, CYP17A1, CYP19A1, CYP21A2
6
Show member pathways
8.1CYP11A1, CYP11B2, CYP17A1, CYP19A1, CYP21A2
7
Show member pathways
7.8CYP11A1, CYP11B2, CYP17A1, CYP19A1, CYP21A2, HSD11B2
8
Show member pathways
7.4CYP11A1, CYP11B2, CYP17A1, CYP19A1, CYP21A2, HSD11B2

GO Terms for genes affiliated with Adrenal Cortical Carcinoma

About this section

Biological processes related to Adrenal Cortical Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
idNameGO IDScoreTop Affiliating Genes
1glucocorticoid metabolic processGO:000821110.5HSD11B2, STAR
2C21-steroid hormone biosynthetic processGO:000670010.4CYP11A1, STAR
3cellular response to gonadotropin stimulusGO:007137110.3CYP17A1, STAR
4response to insecticideGO:001708510.3CYP17A1, STAR
5response to fungicideGO:006099210.3CYP17A1, STAR
6response to herbicideGO:000963510.3CYP17A1, STAR
7organic acid metabolic processGO:000608210.3CYP17A1, STAR
8phthalate metabolic processGO:001896310.3CYP17A1, STAR
9response to steroid hormoneGO:004854510.3CYP17A1, STAR
10regulation of steroid biosynthetic processGO:005081010.2NR5A1, STAR
11cellular response to antibioticGO:007123610.2CYP17A1, STAR
12phenol-containing compound metabolic processGO:001895810.2CYP17A1, STAR
13renal water homeostasisGO:000309110.0CYP11B2, PRKAR1A
14intracellular receptor signaling pathwayGO:003052210.0NR0B1, NR5A1
15Leydig cell differentiationGO:00333279.9CYP17A1, NR0B1
16progesterone metabolic processGO:00424489.9CYP17A1, CYP21A2
17cholesterol metabolic processGO:00082039.9CYP11A1, CYP11B2, STAR
18steroid metabolic processGO:00082029.8HSD11B2, STAR
19glucocorticoid biosynthetic processGO:00067049.8CYP11A1, CYP17A1, HSD11B2
20mineralocorticoid biosynthetic processGO:00067059.2CYP11B2, CYP21A2
21sterol metabolic processGO:00161259.1CYP11A1, CYP11B2, CYP17A1, CYP21A2
22steroid biosynthetic processGO:00066948.6CYP17A1, CYP19A1, CYP21A2, STAR
23small molecule metabolic processGO:00442817.6CYP11B2, CYP19A1, CYP21A2, HSD11B2, PRKAR1A, STAR

Sources for Adrenal Cortical Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet